FORM 8-K


                       SECURITIES AND EXCHANGE COMMISSION


                             Washington, D.C. 20549



                                 CURRENT REPORT


                    Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


         Date of Report (Date of earliest event reported): June 3, 1998



                             MEDTOX SCIENTIFIC, INC.
             (Exact name of registrant as specified in its charter)


                                    Delaware
                 (State or other jurisdiction of incorporation)


1-11394                                                              95-3863205
(Commission File Number)                      (IRS Employer Identification No.)


402 West County Road D
St. Paul, Minnesota                                                       55112
(Address of principal executive offices)                             (Zip Code)


                                 (612) 636-7466
              (Registrant's telephone number, including area code)









Item 4.  Change In Independent Accountants



Effective  May 27,  1998,  the  Registrant  terminated  Ernst & Young LLP as its
independent  accounting  firm. The termination of Ernst & Young LLP was approved
by the Audit Committee of the Board of Directors of the  Registrant.  There were
no disagreements  with Ernst & Young LLP during the last two fiscal years ending
December 31, 1997. Accordingly, Ernst & Young LLP has not advised the Registrant
of (i) the absence of the internal  controls  necessary  for the  Registrant  to
develop reliable  financial  statements,  (ii) any information which would cause
Ernst & Young LLP to no longer  rely on  management's  representations,  or that
Ernst & Young LLP was unwilling to be associated  with the financial  statements
prepared by management,  (iii) any need to expand significantly the scope of its
audit, or any information that if further investigated may (a) materially impact
the fairness or  reliability  of either a previously  issued audit report or the
underlying  financial  statements  or any  financial  statements  for any fiscal
period subsequent to the date of the most recent financial statements covered by
an  audit  report  or (b)  cause  it to be  unwilling  to rely  on  management's
representations or be associated with the Registrant's financial statements,  or
(iv) any information that has come to the attention of Ernst & Young LLP that it
concluded  materially  impacts  the  fairness  or  reliability  of either  (a) a
previously issued audit report or the underlying financial statements or (b) any
financial  statements  issued  or  to  be  issued  covering  any  fiscal  period
subsequent  to the date of the most recent  financial  statements  covered by an
audit report.

Effective  June 3, 1998,  the  Registrant  engaged  Deloitte & Touche LLP as its
independent  accounting firm.  Neither the Registrant or any of its subsidiaries
has had any prior relationships with Deloitte & Touche LLP.









                                   SIGNATURES


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                            MEDTOX Scientific, Inc.




Date:  June 3, 1998                         By: /s/ Peter J. Heath
                                                --------------------

                                            Name:  Peter J. Heath
                                            Title: Vice President of Finance 
                                                   and Chief Financial Officer